Chemotherapy News and Research

Latest Chemotherapy News and Research

NPS Pharmaceuticals proposes underwritten public offering of common stock

NPS Pharmaceuticals, Inc. today announced that it intends to offer, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. In connection with this offering, the Company expects to grant to the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock to cover overallotments, if any.

16 Apr 2010

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, initiated the Company's first clinical trial site in its randomized, single blind, placebo-controlled, Phase 2 clinical trial of ADXS11-001 for the treatment of cervical intraepithelial neoplasia.

16 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

AstraZeneca contributes $1M for expansion of Nemours/Alfred I. duPont Hospital for Children

Surrounded by over 100 Nemours Associates, Rich Fante, President, AstraZeneca, U.S., presented Nemours President David J. Bailey, MD, MBA with a ceremonial check for $1 million, announcing AstraZeneca's contribution to the expansion of Nemours/Alfred I. duPont Hospital for Children in Wilmington, Delaware.

15 Apr 2010

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.

15 Apr 2010

Scientists uncover new genes responsible for cancer, deafness

From deep within the genomes of organisms as diverse as plants, worms and yeast, scientists have uncovered new genes responsible for causing human diseases such as cancer and deafness.

15 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

Researchers identify new strategy for treating acute myeloid leukemia

Researchers have identified a self-feeding "vicious circle" of molecules that keeps acute leukemia cells alive and growing and that drives the disease forward.

15 Apr 2010

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

An ophthalmologist at Washington University School of Medicine in St. Louis is implanting radioactive discs in the eyes of children with a rare cancer in an attempt to save their vision and their eyes.

15 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies, Inc. announced today that Thomas J. Smith, MD FACP, and co-investigator Patrick J. Coyne, MSN, APRN, FAAN, of Virginia Commonwealth University's Massey Cancer Center have completed their open Phase II clinical study examining CTT's Calmare pain therapy medical device's efficacy treating patients suffering with severe pain from chemotherapy induced peripheral neuropathy.

15 Apr 2010

FDA approves Sagent Pharmaceuticals' two ANDAs to market granisetron

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the Company's two abbreviated New Drug Applications to market granisetron hydrochloride injection, USP (granisetron), an antiemetic used to prevent nausea and vomiting caused by chemotherapy.

15 Apr 2010

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

Molecular biologist Jonathan Brody, Ph.D., assistant professor, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, has been awarded a 2010 Pancreatic Cancer Action Network - American Association of Cancer Research Career Development Award in memory of Skip Viragh.

15 Apr 2010

Family support critical for managing patients with chronic health problems

Almost 40 percent of chronically ill older adults in the U.S. live alone, and a majority of those who are married have spouses with at least one chronic illness that can affect their ability to provide support, according to a U-M study published in the journal Chronic Illness.

15 Apr 2010

Study: New anti-cancer agents halt cancer metastasis

ke microscopic inchworms, cancer cells slink away from tumors to travel and settle elsewhere in the body. Now, researchers at Weill Cornell Medical College report in today's online edition of the journal Nature that new anti-cancer agents break down the loping gait these cells use to migrate, stopping them in their tracks.

15 Apr 2010

Australian scientists sequence genome of pancreatic cancer

The International Cancer Genome Consortium which includes researchers from 22 countries is mapping the genomes of different types of cancers. A genome is essentially a blueprint of a human’s DNA. The genetic data of each individual is different and so is the genetic data of the cancer in the individual. The Australian scientists are sequencing the genomes of people suffering from pancreatic cancer.

15 Apr 2010

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.

13 Apr 2010

'Forgotten' cells in brain cancer

Glioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in virtually every case the tumor reappears. One reason for this is that sporadic, infiltrative tumor cells will remain in the brain even after most careful surgery. Researchers at the University of Bonn have now subjected these 'forgotten' cells to closer scrutiny for the first time.

13 Apr 2010

Stem cell scientists receive stimulus grants to study lung and blood disorders

Stem cell scientists at The University of Texas Health Science Center at Houston (UTHealth) were awarded stimulus grants totaling almost $2 million to research experimental treatments for blood disorders and inherited lung diseases affecting children.

13 Apr 2010

Overcoming resistance - new options for the treatment of ovarian cancer

Research on the development of a new therapeutic agent for the treatment of particularly aggressive ovarian cancer has produced some very promising initial findings. In laboratory tests, scientists have succeeded in reducing the resistance of the tumour cells to a natural resistance mechanism with the help of a monoclonal antibody. The results of this project, which was funded by the Austrian Science Fund FWF, have just been published. The project also succeeded in establishing a hitherto unknown connection between so-called "natural killer cells" and the regulated death of cancer cells.

12 Apr 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

NPS Pharmaceuticals proposes underwritten public offering of common stock

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

AstraZeneca contributes $1M for expansion of Nemours/Alfred I. duPont Hospital for Children

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Scientists uncover new genes responsible for cancer, deafness

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Researchers identify new strategy for treating acute myeloid leukemia

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

Targeted therapy MDV3100 is effective for patients with CRPC: Study

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

FDA approves Sagent Pharmaceuticals' two ANDAs to market granisetron

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

Family support critical for managing patients with chronic health problems

Study: New anti-cancer agents halt cancer metastasis

Australian scientists sequence genome of pancreatic cancer

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

'Forgotten' cells in brain cancer

Stem cell scientists receive stimulus grants to study lung and blood disorders

Overcoming resistance - new options for the treatment of ovarian cancer

Cancer Research - Second Edition eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in